Form 4: NewAmsterdam Pharma Co N.V.: Chief Commercial Officer Acquires Options

William A. Jones, Jr., Chief Commercial Officer of NewAmsterdam Pharma Co N.V., reports the acquisition of options to purchase 200,000 ordinary shares.

Summary

• On January 2, 2025, William A. Jones, Jr., the Chief Commercial Officer of NewAmsterdam Pharma Co N.V., acquired options to purchase 200,000 ordinary shares.
• The exercise price of the options is $25.96.
• The options vest over four years, with 25% vesting on January 2, 2026, and the remainder vesting in equal monthly installments over the following three years, contingent upon continued service.
• The options expire on January 2, 2035.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to stock option grants, which is neither particularly positive nor negative. It's a neutral disclosure.

Future Outlook

The vesting schedule indicates a commitment from the executive to remain with the company for the vesting period.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the equity-based compensation of company executives.

Stakeholder Impact

• The granting of options aligns the executive's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates